BioSpace News Archive

City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, presented novel research that seeks to better understand what causes type 1 and type 2 diabetes and how to improve its treatment at the 83rd Scientific Sessions of ADA held June 23 to 26 in San Diego.

Synthetica Bio today announced the official launch of the company and new capital as part of its seed funding.

CoImmune, Inc. announced it has exercised its option to obtain an exclusive license in the Delta-like Ligand 3 -targeted, allogeneic Chimeric Antigen Receptor-Cytokine Induced Killer cell therapy field to interleukin-18 Armored CAR technology under a prior agreement with Memorial Sloan Kettering Cancer Center.

Today, Lovell® Government Services announced a partnership with Freespira, Inc.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced that DA-1726, a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, had been shown to elicit superior weight loss efficacy compared to Semaglutide (SEMA) and Tirzepatide (TIR) in preclinical testing.

Sonendo, Inc. announced the publication of a new study that found the GentleWave System to be significantly more effective than conventional irrigation methods at dissolving tissue during root canal procedures.

DNAnexus Inc. today announced its platform is being used by researchers to access and analyze data from the Mexico City Prospective Study, the largest population health research study of its kind in Mexico.

Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Metrios™ 6 Scanning Transmission Electron Microscope ((S)TEM) — a new-generation, fully automated (S)TEM metrology solution designed to help enhance productivity and deliver data quality assurance for high-volume semiconductor manufacturing.

Celmatix Inc.today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

Santhera Pharmaceuticals announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting held in Pratteln, Switzerland, with a large majority.